Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2012

View Archived Issues

New 5-lipoxygenase inhibitors claimed by Ranbaxy Laboratories

AZD-4694 PET detects Alzheimer's disease pathology in patients

Cancer vaccine shows activity in phase I/II trial

Kampo medicine reduces oxaliplatin-induced peripheral neuropathy in patients with cancer

Novel approach yields first small-molecule ligand for wild-type p53 DNA-binding domain

Panobinostat trial in colorectal cancer yields mixed results

Vanderbilt University patents new indoles

New insulin secretagogues prepared in Japan

Phase II trial investigates GS-7340 as part of a new treatment regimen

Amorcyte kicks off enrollment in phase II AMR-001 study

AC Immune and University of Basel enter research agreement

Sanwa Kagaku Kenkyusho presents novel glucokinase activators

Novel somatostatin receptor ligands reported

FDA approves gel for actinic keratosis

Incyte synthesizes novel PI3K-delta inhibitors

FDA clears updated Vytorin label

Bilastine launched in Brazil

New protease-activated PAR1 receptor antagonists disclosed

FDA expands Keppra indication

Neurocrine Biosciences product gets FDA fast track status

Spectrum Pharmaceuticals enters licensing agreement for Zevalin

CHMP issues opinion on Remicade for ulcerative colitis in children

Phase III afatinib trials begin in head and neck cancer

Targovax secures funding for cancer vaccine research

Initial phase III data show promise for tasimelteon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...